Aflac (NYSE:AFL) posts better-than-expected Q2 earnings as its business in Japan reflected the launch of a new medical product and its business in the U.S. saw small businesses in recovery mode.
"We continued to see improvement and expect a stronger second half of the year in both countries," Chairman and CEO Daniel P. Amos said.
Aflac (NYSE:AFL) 公佈的第二季度收益好於預期,因為其在日本的業務反映了一種新醫療產品的推出,其在美國的業務看到小企業處於復蘇模式。
“我們繼續看到改善,並預計兩國下半年會更強勁,”董事長兼首席執行官丹尼爾·P·阿莫斯 (Daniel P. Amos) 說。
Q2 adjusted EPS of $1.59 beats the consensus estimate of $1.28 and increased from $1.28 in the year-ago quarter.
Q2 total revenue of $5.56B, better than the $5.37B consensus, climbed from $5.41B a year ago.
Adjusted earnings exclude pretax adjusted net investment gains of $85M, or $0.12 per share, in Q2 2021 and pretax adjusted net investment losses of $166M, or $0.23 per share, in Q2 2020.
Aflac Japan: In dollar terms, net premium income decreased 5.4% to $3.0B; pretax adjusted earnings increased 19.7% Y/Y to $1.0B.
Aflac U.S.: Net premium income declined 3.4% Y/Y to $1.4B, mainly due to constrained sales over the past year; pretax adjusted earnings were $413M, down 3.1% Y/Y, primarily driven by lower earned premium and higher expenses despite lower benefits.